Innovator ResMed to reward patient investors

Financial Journalist
Print This Post A A A

The great challenge for value investors is to buy exceptional, undervalued companies. Respiratory medical device manufacturer ResMed Inc fits the first category, but at current prices is trading near fair value. However, on a long-term view, ResMed is a buying opportunity.

A question of timing

The question is not whether to buy ResMed (RMD), but when. Portfolio investors, such as self managed superannuation funds, could justify buying ResMed now, provided they can withstand potential share-price volatility over the next two quarters, and hold the stock for several years.

ResMed (RMD)

Also from this edition